CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The PREDECT project aims to improve drug efficacy predictions by developing advanced in vitro and in vivo models for breast, prostate, and lung cancers. These models will validate novel therapeutic targets through comprehensive biological analyses, enhancing the reliability of preclinical drug discovery.
Traditional preclinical discovery methods, particularly for target validation, poorly predict drug efficacy, causing a high attrition rate in costly late-stage clinical trials.
The PREDECT consortium will focus on complex but transferable, next generation in vitro and in vivo models for breast, prostate and lung cancers.
Models will be investigated for their improved potential to validate novel therapeutic targets.
Known targets, in canonical pathways, will be interrogated for induction of pheno…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Finland, HELSINGIN YLIOPISTO
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Switzerland, Lausanne
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Israel, Rehovot
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
